Neurim Pharma Reports Successful Trial Of Circadin On Alzheimer’s Patients

June 24, 2014 | Israeli pharmaceutical company Neurim Pharmaceuticals reported the completion of an initial efficiency trial of its drug Circadin for the treatment of Alzheimer’s disease, together with existing treatments of the disease. Circadin is currently sold as drug for the treatment of sleeping disorders, based on the delayed release of melatonin. Because melatonin levels are low in the early stages of Alzheimer’s disease, the company decided it would be worthwhile to see if Circadin could help Alzheimer’s patients control the effect of some of the symptoms together with standard methods of treatment. Neurim Pharma was founded by CTO Prof. Nava Zisapel, with the main investors of the company being Nava herself and Yehuda Zisapel. Today, Circadin is sold in over 40 countries for the treatment of sleep disorders.